Skip to main content

NIH’s Priorities Announcement Receives Mixed Responses from Researchers

A list of research priorities released by the NIH addressed many important topics, but ongoing funding uncertainties leave scientists anxious.

Written byShelby Bradford, PhD
| 4 min read
Illustration showing several people’s arms raised and holding signs with faces that either depict neutral yellow faces, unhappy red faces, or happy green faces. This image is emphasizing mixed reactions to an announcement.
Register for free to listen to this article
Listen with Speechify
0:00
4:00

On August 15, 2025, Jayanta Bhattacharya, the director of the National Institutes of Health (NIH), released a statement announcing a “unified strategy” to align the agency’s funding activities with a newly released list of priorities included in the letter. In his statement, Bhattacharya emphasized how NIH funding, originating from taxpayer dollars, is a finite resource, and that the outlined priorities will help the NIH responsibly use the money to address chronic health problems of Americans and invest in next-generation research tools.

The listed priorities include expansion of replication studies and alternative testing models, creation of a “real-world data” resource, and a strategy to implement artificial intelligence in research. Also mentioned is an emphasis on work in autism research, overseeing NIH funding outside the US, and promoting research “on scientifically valid, measurable health outcomes.”

“The priorities are interesting to me as an epidemiologist and as a rheumatologist who sees patients,” said Alexis Ogdie, a researcher at the University of Pennsylvania. She has studied the impact of diet on psoriatic arthritis and was excited to see the role of nutrition in chronic conditions also highlighted as a priority. “I think it's trying to take science and really apply it to patients, and kind of how we're using data in the real world.” She added that the inclusion of research into health disparities eased some of the concerns she had when previous announcements indicated these fields may no longer be invested in.

Continue reading below...

Like this story? Sign up for FREE Newsletter updates:

Latest science news storiesTopic-tailored resources and eventsCustomized newsletter content
Subscribe

A note at the top of the list of priorities explained that the outlined topics were not an exhaustive list of focus areas for the NIH, but instead guidance on specific issues identified by the current administration as gaps in research. The note indicated the NIH would support research not outlined in the priority list as well.

However, amid ongoing changes at the NIH, other researchers felt that some priorities, specifically a statement about training future biomedical scientists, fell flat. Ian Morgan, a postdoctoral fellow and biophysicist at the National Institutes of General Medical Sciences and the National Heart, Lung, and Blood Institute specified how recent reductions in force and funding freezes have stymied research and career development opportunities at the agency.

“It's really good that they're bringing attention to [improving early career researcher training], but they're giving us this, like, shiny red apple…And you take that shiny, red apple, and as soon as you bite into it, you find that it's rotten to its core,” he explained. He added that the director did not seek input from early career researchers on what changes would be helpful to improve their training.

Amid funding cuts to agencies and programs that conduct research into the effects of environmental exposures and chronic diseases, though, he explained that it was unclear how invested the institute was in that work. “They're pointing out really important things that we absolutely should be focusing on and improving on, but when you actually look at what they're doing, it's oftentimes the exact opposite,” he said.

Another concern surrounding the priorities was an announcement in an internal memo that has since been published on social media that called for an internal review of all ongoing research. The stated goal was to ensure that the work aligned with the agency’s priorities.

Ogdie said that she wasn’t sure whether similar rereviews have occurred previously, but added, “Reviewing grants that have already been approved for funding, as someone who has a grant that is approved for funding—and I'm waiting anxiously for [it] to come in the door—that obviously scares me a little bit, that someone could come through and take it out.”

Amidst recent dismissals of dedicated grant reviewers and previous delays in releasing funding, Morgan expressed concern about how this newest round of reviews could further postpone the release of research dollars. “It almost seems designed to slow things down and to shut down biomedical research,” he said.

Coupled with other changes to research funding, Morgan expressed concerns about how the new policies would affect biomedical research long term. He highlighted how many young researchers have been turned away from positions in labs because of funding uncertainties.

Additionally, he said, “By making all of these announcements, it's going to stifle what sort of grants and what type of research is going to be done, because people are afraid that if they say the wrong thing or propose the wrong thing, that they are not going to get their funding.” This, Morgan added, will limit the kind of breakthrough research that leads to radical improvements in health.

Ogdie said that, with all of the continuous changes, many scientists are feeling a lot of anxiety. “We don't really know where things are going. We want to see some stability [and] know that grants are going to be able to be funded,” she said.

While she said that the communications from the NIH have felt more organized and grounded since Bhattacharya joined, she added that the understaffing across the agency and its ripple effects on the whole research ecosystem still concerns her. She is especially worried about the effect on trainees. “This level of uncertainty is especially damaging for those just starting their careers and even those thinking about pursuing a career in research.”

Despite the extent of challenges, Morgan said, “It’s not too late to turn things around.” He added that the most important thing that scientists can do is to express the value of research to people in their community and how these changes affect the ability to do that work. “It behooves us as scientists to go out into the public and talk to our neighbors, talk to our friends, talk to our colleagues, encourage people to not talk down to others around us, but to address legitimate concerns.”

Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • Shelby Bradford, PhD

    Shelby is an Associate Editor at The Scientist. She earned her PhD in immunology and microbial pathogenesis from West Virginia University, where she studied neonatal responses to vaccination. She completed an AAAS Mass Media Fellowship at StateImpact Pennsylvania, and her writing has also appeared in Massive Science. Shelby participated in the 2023 flagship ComSciCon and volunteered with science outreach programs and Carnegie Science Center during graduate school. 

    View Full Profile

Related Topics

You might also be interested in...
Loading Next Article...
You might also be interested in...
Loading Next Article...
The Scientist October Digest cover
October 2026

Antarctica’s Blood Falls Teems With Mysterious Microbial Life

Miles away from the closest ocean, marine microbes thrive in the red ice and mud around Blood Falls, offering clues to microbial adaptation and past climate events.

View this Issue
Find better biologics faster with Stunner and the AI Developability Workcell

Find better biologics faster with Stunner and the AI Developability Workcell

Unchained Labs
An image of microcentrifuge tubes arranged within colorful laboratory racks.

Choose clarity. Choose speed. Choose MyMass™

Refeyn
Characterizing LNP Heterogeneity With Super-Resolution Imaging

Characterizing LNP Heterogeneity With Super-Resolution Imaging

Oni
Conceptual multicolored image of DNA helices.

Exploring the Most Impactful CRISPR Stories

Promega

Products

A monoclonal antibody surrounded by immune cells and red blood cells

CellRaft AIR: Find the Right Antibody-Producing Cells Faster

Cell Microsystems
Maxwell® Rapid ccfDNA Kit

Maxwell® Rapid ccfDNA Kit: Automated Purification of ccfDNA in Under 30 Minutes

Promega
Leica Biosystems, Tempus, and Paige logos side by side, marking the addition of Paige digital pathology AI tools to the Aperio AI Store.

Oncology Researchers Gain AI Cancer Tools in One Platform

Beckman Coulter Life Sciences Logo

Beckman Coulter Life Sciences Launches Vi-CELL BLU 2.0 Software to Advance Data Integrity and GMP Readiness in Cell Analysis